First US Brain-Only PET Clinic Targets Alzheimer's Detection as Diagnostic Demand Expands
Biotech Company Achieves Key Bladder Cancer Milestone in California
Rare Disease Biotech Sell Rating Maintained: Early Clinical Data Fails to Offset Flagship Drug Revenue Decline
Research Report
America's First Brain-Dedicated PET Scanning Clinics: A Turnaround Play for Chart-Savvy Investors?
Contributed Technical Analyst Opinion
Buy Rating Reaffirmed: ALTO-207 TRD Trial on Track
Research Report
Neuroscience Co. Enters Catalyst-Rich 2026 With Multiple Phase 2 Readouts and US$120M Financing
Research Report
Biotech Company Accelerates AI Detection Breakthrough Globally
Durham, NC Biopharma Co. Finds High-Growth Drug Opportunity
Pelthos Therapeutics Inc. (PTHS:NYSEAmerican) delivered massive growth from its drug launch, with bullish forecasts signaling upside, according to analysts.Life Sciences Firm Advances Massive US$2.4B Market Opportunity
Cleantech and life sciences leader BioLargo Inc. (BLGO:OTCQX) announces that clinical experiences with ViaCLYR were presented at a symposium in Hawaii.An AI-Powered Doctor & Patient Platform: Why This North American Provider is Gaining Market Momentum
Contributed Technical Analyst Opinion
Technical Analyst Stewart Thomson explains why he likes Rocket Doctor AI Inc. (AIDR:CSE; TREIF:OTC; 939:FRA). Langhorne, PA Biotech Eyes Mid-2026 Molbreevi Launch
Research Report
H.C. Wainwright reiterated its rating and price target on Savara Inc. (SVRA:NASDAQ), citing a cleared regulatory path for Molbreevi with an August 22, 2026, PDUFA date, no planned FDA Advisory Committee, and accelerating commercial preparations targeting 1,700 accounts and 4,500 healthcare professionals ahead of a potential approval in the rare autoimmune PAP market. Bothell, WA Bio Co. Poised for 17-20% Revenue Growth in 2026 as Cell Therapy Market Expands
Research Report
BioLife Solutions Inc. (BLFS:NASDAQ) reported strong 2025 results. The company is now a pure-play cell processing business, expecting double-digit growth driven by expanding cell and gene therapy adoption, according to an H.C. Wainwright & Co. research note. A New Infection Control Platform Launched
Contributed Technical Analyst Opinion
John Newell of John Newell & Associates shares his thoughts on BioLargo Inc. (BLGO:OTCQX) to explain why he thinks the stock is a Speculative Buy. Analyst Maintains Spec Buy on Biotech After Interim SAT-3247 DMD Data
Research Report
Leede Financial maintained its rating on Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ), with a US$16.00 price target following updated interim Phase II SAT-3247 data from the TRAILHEAD trial in Duchenne muscular dystrophy. Cannabis Producer Moves to the TSX as Analyst Flags Major Expansion Potential
Cannara Biotech Inc. (LOVE:TSX; LOVFF:OTCQX; BCB0:FSE) began trading on the Toronto Stock Exchange on March 2 after graduating from the TSX Venture Exchange. Atrium Research initiated coverage with a BUY rating and CA$3.00 target, citing best-in-class EBITDA margins of 29%.Medical Co.'s TULSA-PRO Installed Base Growth and CAPTAIN Trial Data Could Accelerate Adoption in 2026"
Research Report
Leede Financial maintained its rating on Profound Medical Corp. (PROF:NASDAQ; PRN:TSX), citing strong TULSA-PRO capital sales, expanding installed base, and upcoming CAPTAIN trial results at EAU meeting as key catalysts. 
Streetwise Key Charts
